Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 4/20 | 0.62 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.53 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.53 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.53 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.53 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.51 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA7 | P43166 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16839911 | 0.91 | LTA4H (0.57) | LTA4HALOX5HDAC3HDAC4HDAC1 | |
| SCHEMBL6136275 | 0.91 | LTA4H (0.67) | LTA4HALOX5HDAC3HDAC4HDAC1 | |
| SCHEMBL16761953 | 0.88 | LTA4H (0.66) | LTA4HALOX5POLBSIGMAR1 | |
| SCHEMBL23792311 | 0.88 | LTA4H (0.61) | LTA4HALOX5POLBTDP1CYP4F2 | |
| SCHEMBL5176477 | 0.88 | LTA4H (0.74) | LTA4H | |
| SCHEMBL7415640 | 0.86 | LTA4H (0.63) | LTA4HALOX5HDAC3HDAC4HDAC1 | |
| SCHEMBL549268 | 0.86 | LTA4H (0.60) | LTA4HALOX5HDAC3HDAC1HDAC2 | |
| SCHEMBL9543993 | 0.85 | CA12 (0.68) | LTA4HTDP1CA12CA7CA9 | |
| Hydrochloric Acid SCHEMBL27717592 | 0.84 | LTA4H (0.61) | LTA4HALOX5HDAC3HDAC4HDAC1 | |
| SCHEMBL7003303 | 0.84 | KMT2A (0.63) | LTA4HCYP4F2CYP4A11SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12157731-B2 | EIF4E inhibitors and uses thereof | PIC Therapeutics, Inc. (US) | 2024-12-03 | — | — | US | disclosed |
| EP-4422619-A1 | INHIBITORS OF VIRAL HELICASES BINDING TO A NOVEL ALLOSTERIC BINDING SITE | Eisbach Bio GmbH (DE) | 2024-09-04 | — | — | EP | disclosed |
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-12-14 | — | — | US | disclosed |
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-12-14 | — | — | US | disclosed |
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-12-14 | — | — | US | disclosed |
| US-11753403-B2 | EIF4E inhibitors and uses thereof | PIC Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753403-B2 | EIF4E inhibitors and uses thereof | PIC Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753403-B2 | EIF4E inhibitors and uses thereof | PIC Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| WO-2023161427-A1 | VIRAL COMBINATION THERAPY | EISBACH BIO GMBH (DE) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023073222-A1 | INHIBITORS OF VIRAL HELICASES BINDING TO A NOVEL ALLOSTERIC BINDING SITE | EISBACH BIO GMBH (DE) | 2023-05-04 | — | — | WO | disclosed |
| US-5648368-A | ANTICOAGULANTS | MERCK & CO., INC. (US) | 1997-07-15 | — | — | US | disclosed |
| EP-0673247-A4 | FIBRINOGEN RECEPTOR ANTAGONISTS. | MERCK & CO INC (US) | 1996-05-01 | — | — | EP | disclosed |
| EP-0540334-B1 | Fibrinogen receptor antagonists | MERCK & CO INC (US) | 1996-01-03 | — | — | EP | disclosed |
| EP-0673247-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 1995-09-27 | — | — | EP | disclosed |
| WO-1995017397-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1995-06-29 | — | — | WO | disclosed |
| US-5416099-A | Fibrinogen receptor antagonists | MERCK & CO., INC. (US) | 1995-05-16 | — | — | US | disclosed |
| US-5389631-A | A piperidinyl quinazoline or 1,3-benzodiazepine antiagglomerants of blood | MERCK & CO., INC. (US) | 1995-02-14 | — | — | US | disclosed |
| WO-1994012181-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1994-06-09 | — | — | WO | disclosed |
| US-5272158-A | Fibrinogen receptor antagonists | MERCK & CO., INC. (US) | 1993-12-21 | — | — | US | disclosed |
| EP-0540334-A1 | Fibrinogen receptor antagonists | MERCK & CO. INC. (US) | 1993-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | EIF4E, EIF4EBP1, EIF4A1 | LTA4H 4175/4885ALOX5 4343/4885HDAC3 1946/4885 |
| US-12157731-B2 | EIF4E inhibitors and uses thereof | EIF4E, EIF4EBP1, EIF4A1 | LTA4H 4175/4885ALOX5 4343/4885HDAC3 1946/4885 |
| US-11753403-B2 | EIF4E inhibitors and uses thereof | EIF4E, EIF4EBP1, EIF4A1 | LTA4H 4175/4885ALOX5 4343/4885HDAC3 1946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.